Aratana Therapeutics Inc. started an underwritten public offering for $35 million of its common stock.
The company also plans to grant the underwriters an option to buy up to an additional $5.3 million of its common stock.
Barclays and Credit Suisse are acting as joint book-running managers for the offering.
